Suppr超能文献

胃癌患者预后免疫炎症指数的建立与验证。

Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer.

机构信息

Department of Radiology, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China.

Zhi-Chang Ba and Xi-Qing Zhu.

出版信息

World J Gastroenterol. 2024 Jun 28;30(24):3059-3075. doi: 10.3748/wjg.v30.i24.3059.

Abstract

BACKGROUND

Studies have demonstrated the influence of immunity and inflammation on the development of tumors. Although single biomarkers of immunity and inflammation have been shown to be clinically predictive, the use of biomarkers integrating both to predict prognosis in patients with gastric cancer remains to be investigated.

AIM

To investigate the prognostic and clinical significance of inflammatory biomarkers and lymphocytes in patients undergoing surgical treatment for gastric cancer.

METHODS

Univariate COX regression analysis was performed to identify potential prognostic factors for patients with gastric cancer undergoing surgical treatment. Least absolute shrinkage and selection operator-COX (LASSO-COX) regression analysis was performed to integrate these factors and formulate a new prognostic immunoinflammatory index (PII). The correlation between PII and clinical characteristics was statistically analyzed. Nomograms incorporating the PII score were devised and validated based on the time-dependent area under the curve and decision curve analysis.

RESULTS

Patients exhibiting elevated neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and systemic immune inflammatory index displayed inferior progression-free survival (PFS) and overall survival (OS). Conversely, low levels of CD3(+), CD3(+) CD8(+), CD4(+)CD8(+), and CD3(+)CD16(+)CD56(+) T lymphocytes were associated with improved PFS and OS, while high CD19(+) T lymphocyte levels were linked to worse PFS and OS. The PII score demonstrated associations with tumor characteristics (primary tumor site and tumor size), establishing itself as an independent prognostic factor for both PFS and OS. Time-dependent area under the curve and decision curve analysis affirmed the effectiveness of the PII-based nomogram as a robust prognostic predictive model.

CONCLUSION

PII may be a reliable predictor of prognosis in patients with gastric cancer undergoing surgical treatment, and it offers insights into cancer-related immune-inflammatory responses, with potential significance in clinical practice.

摘要

背景

研究表明,免疫和炎症对肿瘤的发展有影响。虽然已经证明了单一的免疫和炎症生物标志物具有临床预测价值,但利用整合这两种标志物来预测胃癌患者预后的方法仍有待研究。

目的

探讨炎症生物标志物和淋巴细胞对接受手术治疗的胃癌患者预后的预测价值和临床意义。

方法

采用单因素 COX 回归分析筛选出与接受手术治疗的胃癌患者预后相关的潜在预后因素。采用最小绝对收缩和选择算子 COX(LASSO-COX)回归分析对这些因素进行整合,并构建新的预后免疫炎症指数(PII)。对 PII 与临床特征的相关性进行统计学分析。根据时间依赖性曲线下面积和决策曲线分析,构建并验证包含 PII 评分的列线图。

结果

中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值和全身免疫炎症指数升高的患者无进展生存期(PFS)和总生存期(OS)较差。相反,CD3(+)、CD3(+) CD8(+)、CD4(+) CD8(+)和 CD3(+) CD16(+) CD56(+)T 淋巴细胞水平较低与 PFS 和 OS 改善相关,而 CD19(+)T 淋巴细胞水平较高与 PFS 和 OS 较差相关。PII 评分与肿瘤特征(原发肿瘤部位和肿瘤大小)相关,是 PFS 和 OS 的独立预后因素。时间依赖性曲线下面积和决策曲线分析证实了基于 PII 的列线图作为一种强大的预后预测模型的有效性。

结论

PII 可能是接受手术治疗的胃癌患者预后的可靠预测指标,它提供了有关癌症相关免疫炎症反应的信息,在临床实践中具有潜在意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2471/11230058/efedf409c378/WJG-30-3059-g005.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验